GlassScriptPhysician profile
Melissa Joan Terchek
NPI 1639280753
$7,387.30
in general payments reported to CMS, 2019-2025
34 companies · $49.61 in 2025
The $49.61 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,899 · 2020: $1,217 · 2021: $1,174 · 2022: $2,939 · 2023: $49.90 · 2024: $58.20 · 2025: $49.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $157.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,428.28 | 2019-2022 | |
| Glaxosmithkline, LLC. | $726.07 | 2019-2025 | Shingrix |
| Amgen INC. | $636.04 | 2019-2025 | Tavneos |
| Pfizer INC. | $620.07 | 2019-2022 | |
| Ucb, INC. | $521.32 | 2019-2022 | |
| Janssen Biotech, INC. | $473.48 | 2019-2023 | Tremfya, Simponi Aria |
| Supernus Pharmaceuticals, INC. | $419.84 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $383.77 | 2019-2022 | |
| Lilly USA, LLC | $374.70 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $237.30 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $226.03 | 2019-2022 | |
| Radius Health, INC. | $210.88 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $155.03 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $118.49 | 2019 | |
| Mallinckrodt Hospital Products INC. | $97.41 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $71.97 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $71.54 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $70.97 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.65 | 2019-2021 | |
| Celgene Corporation | $62.80 | 2019 | |
| Genentech USA, INC. | $50.38 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $44.42 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $42.51 | 2019 | |
| Argenx US, INC. | $34.75 | 2023 | Vyvgart |
| Amneal Pharmaceuticals LLC | $34.15 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.37 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $33.25 | 2020-2021 | |
| Horizon Therapeutics Plc | $30.36 | 2022 | |
| Jazz Pharmaceuticals INC. | $23.79 | 2022 | |
| Nevro Corp. | $21.49 | 2022 | |
| Ani Pharmaceuticals, INC. | $20.02 | 2022 | |
| Pacira Therapeutics, INC. | $14.73 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.55 | 2025 | Rexulti |
| Biodelivery Sciences International, INC. | $13.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Terchek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.